Richard Sullivan

Summary

Affiliation: Cancer Research UK
Country: UK

Publications

  1. ncbi Clinical trial design in oncology: protocol design
    Richard Sullivan
    Cancer Research UK, London
    Lancet Oncol 5:759. 2004
  2. ncbi Medicinal mushrooms and cancer therapy: translating a traditional practice into Western medicine
    Richard Sullivan
    Cancer Research UK, 61 Lincoln s Inn Field, London W2A 3PX, United Kingdom
    Perspect Biol Med 49:159-70. 2006
  3. pmc European Non-Communicable Respiratory Disease Research, 2002-13: Bibliometric Study of Outputs and Funding
    Mursheda Begum
    Department of Cancer Studies, Division of Cancer Epidemiology and Population Health, Guy s Hospital, King s College London, London, United Kingdom
    PLoS ONE 11:e0154197. 2016
  4. doi What really matters in cancer?: Putting people back into the heart of cancer policy
    Arnie Purushotham
    King s College, Institute of Cancer Policy, London, United Kingdom
    Eur J Cancer 49:1669-72. 2013
  5. doi The state of research and development in global cancer surgery
    Arnie D Purushotham
    King s College London, Strand, London, United Kingdom
    Ann Surg 255:427-32. 2012
  6. pmc A survey of public funding of cancer research in the European union
    Seth Eckhouse
    European Cancer Research Managers Forum, London, United Kingdom
    PLoS Med 3:e267. 2006
  7. doi Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity
    Richard Sullivan
    Department of Anatomy and Cell Biology, Queen s University, Botterell Hall, Room 859, Kingston, Ontario, Canada K7L 3N6
    Mol Cancer Ther 7:1961-73. 2008
  8. ncbi Chemosensitization of cancer by nitric oxide
    Richard Sullivan
    Department of Anatomy and Cell Biology, Queen s University, Kingston, Ontario, Canada K7L 3N6
    Curr Pharm Des 14:1113-23. 2008
  9. doi The good, the bad, and the ugly: effect of regulations on cancer research
    Richard Sullivan
    Department of Social Policy Health, Population and Society, London School of Economics and Political Science, London WC2A 2AE, UK
    Lancet Oncol 9:2-3. 2008
  10. ncbi Hypoxia-driven selection of the metastatic phenotype
    Richard Sullivan
    Department of Anatomy and Cell Biology, Queen s University, Kingston, ON K7L 3N6, Canada
    Cancer Metastasis Rev 26:319-31. 2007

Collaborators

  • Gregg Semenza
  • Mursheda Begum
  • Grant Lewison
  • Arnie Purushotham
  • Arnie D Purushotham
  • Lisa J Frederiksen
  • Seth Eckhouse
  • Elena Pallari
  • John S F Wright
  • David J Flavell
  • Catherine Burton
  • Derek Stewart
  • Jocelyn Cornwell
  • Brian M Bennett
  • Lori R Maxwell
  • Charles H Graham
  • Michael A Adams
  • D Robert Siemens
  • Shannyn K Macdonald-Goodfellow
  • Sopsamorn U Flavell

Detail Information

Publications14

  1. ncbi Clinical trial design in oncology: protocol design
    Richard Sullivan
    Cancer Research UK, London
    Lancet Oncol 5:759. 2004
  2. ncbi Medicinal mushrooms and cancer therapy: translating a traditional practice into Western medicine
    Richard Sullivan
    Cancer Research UK, 61 Lincoln s Inn Field, London W2A 3PX, United Kingdom
    Perspect Biol Med 49:159-70. 2006
    ....
  3. pmc European Non-Communicable Respiratory Disease Research, 2002-13: Bibliometric Study of Outputs and Funding
    Mursheda Begum
    Department of Cancer Studies, Division of Cancer Epidemiology and Population Health, Guy s Hospital, King s College London, London, United Kingdom
    PLoS ONE 11:e0154197. 2016
    ..Just over 37% of papers had no specific funding and depended on institutional support from universities and hospitals. ..
  4. doi What really matters in cancer?: Putting people back into the heart of cancer policy
    Arnie Purushotham
    King s College, Institute of Cancer Policy, London, United Kingdom
    Eur J Cancer 49:1669-72. 2013
    ....
  5. doi The state of research and development in global cancer surgery
    Arnie D Purushotham
    King s College London, Strand, London, United Kingdom
    Ann Surg 255:427-32. 2012
    ..The objective of this study was to perform an analysis of global cancer surgery research and development trends over the last 10 years across 21 countries...
  6. pmc A survey of public funding of cancer research in the European union
    Seth Eckhouse
    European Cancer Research Managers Forum, London, United Kingdom
    PLoS Med 3:e267. 2006
  7. doi Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity
    Richard Sullivan
    Department of Anatomy and Cell Biology, Queen s University, Botterell Hall, Room 859, Kingston, Ontario, Canada K7L 3N6
    Mol Cancer Ther 7:1961-73. 2008
    ..These results support a requirement for HIF-1 in the adaptations leading to drug resistance and reveal that decreased drug-induced senescence is also an important contributor to the development of hypoxia-induced resistance...
  8. ncbi Chemosensitization of cancer by nitric oxide
    Richard Sullivan
    Department of Anatomy and Cell Biology, Queen s University, Kingston, Ontario, Canada K7L 3N6
    Curr Pharm Des 14:1113-23. 2008
    ....
  9. doi The good, the bad, and the ugly: effect of regulations on cancer research
    Richard Sullivan
    Department of Social Policy Health, Population and Society, London School of Economics and Political Science, London WC2A 2AE, UK
    Lancet Oncol 9:2-3. 2008
  10. ncbi Hypoxia-driven selection of the metastatic phenotype
    Richard Sullivan
    Department of Anatomy and Cell Biology, Queen s University, Kingston, ON K7L 3N6, Canada
    Cancer Metastasis Rev 26:319-31. 2007
    ..Through regulation of these critical molecular targets, hypoxia promotes each step of the metastatic cascade and selects tumor cell populations that are able to escape the unfavorable microenvironment of the primary tumor...
  11. ncbi Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling
    Lisa J Frederiksen
    Department of Anatomy, Queen s University, Kingston, Ontario, Canada
    Clin Cancer Res 13:2199-206. 2007
    ..Here, we determined whether chemosensitization by NO mimetics requires cGMP-dependent signaling and whether low concentrations of NO mimetics can chemosensitize tumors in vivo...
  12. pmc United Kingdom research governance strategy: reforming clinical research and development in England
    Richard Sullivan
    BMJ 328:49-50; author reply 50. 2004
  13. ncbi European Clinical Trials Directive: responses made to MHRA consultation letter MLX 287
    David J Flavell
    Lancet 362:1415. 2003